Test - Ascendis Pharma DK

NEWS RELEASES

September 3, 2024

Ascendis Pharma Reports Second Quarter 2024 Financial Results

August 28, 2024

Ascendis Pharma to Report Second Quarter 2024 Financial Results and Provide Business Update on September 3, 2024

August 12, 2024

FDA Approves YORVIPATH® (Palopegteriparatide) as the First and Only Treatment for Hypoparathyroidism in Adults

Preclinical

Phase 1

Phase 2

Phase 3

TransCon hGH

Pediatric growth hormone deficiency2

test

Phase 1

test

Adult growth hormone deficiency

Phase 1

TransCon PTH

Adult hypoparathyroidism

Phase 2

Preclinical

Phase 1

Phase 2

Phase 3

sss

Phase 1

sdsd

sss

Phase 2

sss

sds

Phase 3

You are about to access www.ascendispharma.com.
Click below if you wish to proceed.

GO CANCEL

You are about to leave the Ascendis Pharma website and will continue on an external website. Ascendis Pharma takes no responsibility for the content of such external website

GO CANCEL